Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

bemdaneprocel

Phase 3Cell therapy

BBlueRock Therapeutics

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parkinson's Disease (PD)Recruiting

Parkinson's Disease (PD)Phase 3

Recruiting

Timeline

Expected Milestones

Q1 2032

Phase 3Recruiting

Parkinson's Disease (PD)

NCT06944522

Clinical

Trials by Indication[1]

Parkinson's Disease (PD)1 trial

exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinson's Disease

Recruiting·BBlueRock Therapeutics·Phase 3·NCT06944522·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for bemdaneprocel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — bemdaneprocel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for bemdaneprocel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BlueRock Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: BBlueRock Therapeutics

Related News